An Early Phase 1 interventional study of ZP7570 and Placebo in Healthy, sponsored by Zealand Pharma. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-02.
Sponsored by Zealand Pharma · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a randomised, double-blind, placebo-controlled, multiple ascending dose trial in healthy subjects, randomised to ZP7570 or placebo within each cohort
Forty subjects are planned to be studied in four cohorts in this multiple ascending dose trial. Ten subjects will be allocated to four dose levels. Intermediate dose levels may be applied. A sentinel dosing approach (sequential dosing) will be applied. The entire observation period comprises 51 days starting with a 96 hours in-house stay after the first dose injection, where discharge is planned for Day 5, followed by one outpatient visit. For the second and the third injection dose a 36 hours in-house stay is planned. After the fourth dose injection there is also a 96 hour in-house stay where discharge is planned for Day 26, followed by five outpatient visits and an End of Trial Visit on Day 51. A blinded evaluation of each cohort will be performed by a Trial Safety Group to determine whether the trial will progress to the next planned dose level based on the stopping rules specified in the protocol.
Zealand Pharma is the lead sponsor of 43 studies on the registry; 5 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 8 (47%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Four ascending doses of ZP7570
Drug: ZP7570
Corresponding volume of placebo
Drug: Placebo
Each subject will be randomly allocated to multiple doses of ZP7570 at one of four dose levels in each cohort.
Also known as: Dual GLP-1R/GLP-2R agonist
Placebo; corresponding volume
Safety and Tolerability - Incidence of treatment emergent adverse events as assessed by type and severity
The incidence, type and severity of treatment emergent adverse events
Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing) ]
Pharmacokinetics - Area under the plasma concentration-time curve - through
AUCτ, Area under the plasma concentration-time curve from zero to through concentration.
Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)
Pharmacokinetics - Area under the plasma concentration-time curve - infinity
AUCinf, Area under the plasma concentration-time curve from zero to infinity concentration.
Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)
Pharmacokinetics - Area under the plasma concentration-time curve - last
AUClast, Area under the plasma concentration-time curve-from zero to last concentration.
Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)
Pharmacokinetics - Maximum plasma concentration - Cmax
Cmax, Measured maximum plasma drug concentration after dosing
Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)
Pharmacokinetics - Time to maximum plasma concentration - Tmax
Tmax, Sampling time until reaching Cmax after dosing
Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)
Pharmacokinetics - Elimination rate constant - λz
λz, Elimination rate constant
Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)
Pharmacokinetics - Half-life - t½
t½, Half-life of ZP7570
Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)
Pharmacokinetics - Volume of distribution - Vz/f
Vz/f, Apparent volume of distribution of ZP7570 during terminal phase
Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)
Pharmacokinetics - Body clearance - CL/f
CL/f, Apparent total body clearance
Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)
Pharmacokinetics - Mean residence time - MRT
MRT, Mean residence time
Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)
Pharmacodynamics - Acetaminophen concentration-time curves
Acetaminophen concentration-time curves following ingestion of mixed meal test and acetaminophen
Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the the forth dose
Pharmacodynamics - Maximum acetaminophen concentration - Cmax
Cmax, maximum acetaminophen concentration following ingestion of mixed meal test and acetaminophen
Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the the forth dose
Pharmacodynamics - Time to maximum acetaminophen concentration - Tmax
Tmax, Time to maximum acetaminophen concentration following ingestion of mixed meal test and acetaminophene
Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose
Pharmacodynamics - Area under the concentration-time curve - AUCacetaminohen,0-60min
AUCacetaminohen,0-60min, area under the acetaminophen concentration-time curve from 0 to 60 min post-ingestion
Time frame: From time 0 to 60 minutes at baseline, 24 hours after a single dose and 24 hours after the the forth dose
Pharmacodynamics - Area under the concentration-time curve - AUCacetaminohen,0-240min
AUCacetaminohen,0-240min, area under the acetaminophen concentration -time curve from 0 to 240 min post-ingestion
Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose
Pharmacodynamics - Plasma glucose concentration-time curves
Plasma glucose concentration-time curves following ingestion of mixed meal test and acetaminophen
Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the the forth dose
Pharmacodynamics - Maximum plasma glucose concentration - Cmax
Cmax, Maximum plasma glucose concentration following ingestion of mixed meal test and acetaminophen
Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the the forth dose
Pharmacodynamics - Time to maximum plasma glucose concentration - Tmax
Tmax, Time to maximum plasma glucose concentration following ingestion of mixed meal test and acetaminophen
Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose
Pharmacodynamics - Area under the concentration-time curve - AUCplasma glucose,0-60min
AUCplasma glucose,0-60min, area under the plasma glucose concentration-time curve from 0 to 60 min post-ingestion
Time frame: From time 0 to 60 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose
Pharmacodynamics - Area under the concentration-time curve - AUCplasma glucose,0-240min
AUCplasma glucose,0-240min, area under the acetaminophen concentration -time curve from 0 to 240 min post-ingestion
Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose
Pharmacodynamics - Insulin concentration-time curves
Insulin concentration-time curves following ingestion of mixed meal test and acetaminophen
Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose
Pharmacodynamics - Maximum insulin concentration - Cmax
Cmax, Maximum insulin concentration following ingestion of mixed meal test and acetaminophen
Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose
Pharmacodynamics - Time to maximum insulin concentration - Tmax
Tmax, Time to maximum insulin concentration following ingestion of mixed meal test and acetaminophen
Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose
Pharmacodynamics - Area under the concentration-time curve - AUCinsulin,0-60min
AUCinsulin,0-60min, area under the insulin concentration-time curve from 0 to 60 min post-ingestion
Time frame: From time 0 to 60 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose
Pharmacodynamics - Area under the concentration-time curve - AUCinsulin, 0-240min
AUCinsulin,0-240min, area under the insulin concentration-time curve from 0 to 240 min post-ingestion
Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose
Pharmacodynamics - Glucagon concentration-time curves (optional)
Glucagon concentration-time curves following ingestion of mixed meal test and acetaminophen
Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose
Pharmacodynamics - Maximum glucagon concentration - Cmax (optional)
Cmax, Maximum glucagon concentration following ingestion of mixed meal test and acetaminophen
Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose
Pharmacodynamics - Time to maximum glucagon concentration - Tmax (optional)
Tmax, Time to maximum glucagon concentration following ingestion of mixed meal test and acetaminophen
Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose
Pharmacodynamics - Area under the concentration-time curve - AUCglucagon,0-60min (optional)
AUCglucagon,0-60min, area under the glucagon concentration-time curve from 0 to 60 min post-ingestion
Time frame: From time 0 to 60 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose
Pharmacodynamics - Area under the concentration-time curve - AUCglucagon, 0-240min (optional)
AUCglucagon,0-240min, area under the glucagon concentration-time curve from 0 to 240 min post-ingestion
Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose
Pharmacodynamics - Free fatty acids concentration-time curves
Free fatty acids concentration-time curves following ingestion of mixed meal test and acetaminophen
Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose
Pharmacodynamics - Maximum free fatty acids concentration - Cmax
Cmax, Maximum free fatty acids concentration following ingestion of mixed meal test and acetaminophen
Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose
Pharmacodynamics - Time to maximum free fatty acids concentration - Tmax
Tmax, Time to maximum free fatty acids concentration following ingestion of mixed meal test and acetaminophen
Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose
Pharmacodynamics - Area under the concentration-time curve - AUCfree fatty acids, 0-60min
AUCfree fatty acids,0-60min, area under the free fatty acids concentration-time curve
Time frame: From time 0 to 60 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose
Pharmacodynamics - Area under the concentration-time curve - AUCfree fatty acids, 0-240min
AUCfree fatty acids,0-240min, area under the free fatty acids concentration-time curve
Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose
Pharmacodynamics - Triglycerides concentration-time curves
Triglycerides concentration-time curves following ingestion of mixed meal test and acetaminophen
Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose
Pharmacodynamics - Maximum triglycerides concentration - Cmax
Cmax, Maximum triglycerides concentration following ingestion of mixed meal test and acetaminophen
Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose
Pharmacodynamics - Time to maximum triglycerides concentration - Tmax
Tmax, Time to maximum triglycerides concentration following ingestion of mixed meal test and acetaminophen
Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose
Pharmacodynamics - Area under the concentration-time curve - AUCtriglycerides, 0-60min
AUCtriglycerides,0-60min, area under the triglycerides concentration-time
Time frame: From time 0 to 60 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose
Pharmacodynamics - Area under the concentration-time curve - AUCtriglycerides,0-240min
AUCtriglycerides,0-240min, area under the triglycerides concentration-time curve
Time frame: From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose
Anti-ZP7570 antibodies - Incidence and titres
Overall anti-ZP7570 antibody incidence and titers. Incidence of anti-ZP7570 antibodies cross-reacting with endogenous GLP-1 or GLP-2.
Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)
Safety Lab - Haematological values vs. reference ranges and baseline
Abnormal values or changes in haematology.
Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)
Safety Lab - Clinical chemistry values vs. reference ranges and baseline
Abnormal values or changes in chemical chemistry
Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)
Safety Lab - Urinalysis values vs. reference ranges and baseline
Abnormal values or changes in urinalysis
Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)
Safety - Vital signs: blood pressure
Changes in diastolic and systolic blood pressure (in mmHg)
Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)
Safety - Vital signs: pulse
Changes in pulse (beats per minute)
Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)
Safety - Physical Examination
Changes in physical examination of the body. Outcome will be measured as 'normal' or 'abnormal', if abnormal as 'not clinically significant' or 'clinically significant'.
Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)
Safety - ECG
Changes or abnormalities in ECG parameters (in ms): Heart rate, PR, QRS, QT, QTcF
Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)
Safety - Injection site reactions
Occurrence of injection site reactions
Time frame: From time 0 to 51 days after first dosing (29 days after fourth dosing)
Ran from Oct 2020 to primary completion in Aug 2021, 10 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapiglutide